Cancer Treatment Cancer Immunotherapy Checkpoint Inhibitors Cancer Vaccines Vaccine Development mRNA Technology Vaccines Drug Treatments PD-1 Inhibitors Cytokine Therapy Combination Therapy Cellular Therapy Side Effects Cellular Immunotherapy CAR-T Therapy Personalized Medicine Cellular Therapies CAR-T Cell Therapy Immune Cells Natural Killer Cells Antibody-Drug Conjugates Treatment Methods Targeted Therapy Cell Therapy Dendritic Cell Vaccines Infection Treatment Precision Medicine Bispecific T-cell Engagers Durvalumab T-Cell Therapy Nanobody Therapy Cytokines Interleukin Therapy Autoimmune Diseases Immune Response Mechanisms Chimeric Antigen Receptor Therapy Monoclonal Antibodies CAR T-cell Therapy Antibody Therapy Immune Response Enhancement Clinical Trials Innate Immune System T-cell Therapy Nivolumab PD-1 Inhibition CAR T Cell Therapy T Cell Therapy Cognitive Effects Cost of Treatment Immune Modulation Cancer Types Cancer Immunology Biomarkers Immune Checkpoint Inhibitors Oncolytic Virus Therapy PD-1
Investigators report deeper remissions with less intensive strategies, prompting plans for biomarker-guided personalization.
